All In Biotech

Drug Trial Radar · NCT07720596

Molnupiravir and COVID-19 Mortality Reduction in the Omicron Era

Effect of Molnupiravir on COVID-19 Mortality in the Omicron Era: A Real-World Target Trial Emulation Using Complete Czech Nationwide Data

Last checked: Nov 19, 2026Latest source record: Sep 15, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

1,795,570

Actual

Start

Jan 1, 2022

Primary completion

Dec 31, 2024

Study completion Dec 31, 2024

Sponsor

Lead sponsor
Charles University, Czech RepublicAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Institute of Health Information and Statistics of the Czech Republic
First posted
Jul 22, 2026

More drug trials from this sponsor

Design

Study type
Observational
Who can join
All sexes, from 20 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This retrospective real-world target trial emulation uses complete Czech nationwide registry data to evaluate whether molnupiravir treatment is associated with lower COVID-19 mortality during the Omicron era. The study compares adults with confirmed acute COVID-19 treated with molnupiravir in addition to standard care versus matched controls treated with standard care without molnupiravir. Patients are followed for three months from time zero, and primary endpoints are the COVID-19 case fatality rate and all-cause mortality.

Conditions

  • COVID-19
  • SARS-CoV-2

Interventions

  • MolnupiravirDrug

    800 mg of molnupiravir administered twice daily, i.e., four capsules every 12 hours for five days.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. COVID-19 CFR comparing patients treated with molnupiravir versus those not treated with molnupiravir.Time frame: Three months from time zero.
  2. ACM comparing patients treated with molnupiravir versus those not treated with molnupiravir.Time frame: Three months from time zero.

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Department of Pharmacology, Third Faculty of Medicine, Charles University

    Prague, Czechia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.